Diffuse large B cell lymphoma laboratory tests: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 8: | Line 8: | ||
* Serum lactate dehydrogenase (LDH) | * Serum lactate dehydrogenase (LDH) | ||
* Comprehensive metabolic panel | * Comprehensive metabolic panel | ||
* Lymph node or extranodal tissue biopsy | |||
* CT chest/abdominal/pelvic with oral and intravenous contrast (unless co-existent renal insufficiency) | * CT chest/abdominal/pelvic with oral and intravenous contrast (unless co-existent renal insufficiency) | ||
* MUGA scan or echocardiograms are recommended when anthracyclines and anthracenedione containing regimens are used | * MUGA scan or echocardiograms are recommended when anthracyclines and anthracenedione containing regimens are used |
Revision as of 13:30, 25 August 2015
Diffuse large B cell lymphoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Diffuse large B cell lymphoma laboratory tests On the Web |
American Roentgen Ray Society Images of Diffuse large B cell lymphoma laboratory tests |
Directions to Hospitals Treating Diffuse large B cell lymphoma |
Risk calculators and risk factors for Diffuse large B cell lymphoma laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Laboratory Tests
Laboratory studies include[1]
- Complete Blood Picture
- Serum lactate dehydrogenase (LDH)
- Comprehensive metabolic panel
- Lymph node or extranodal tissue biopsy
- CT chest/abdominal/pelvic with oral and intravenous contrast (unless co-existent renal insufficiency)
- MUGA scan or echocardiograms are recommended when anthracyclines and anthracenedione containing regimens are used
- Bone marrow biopsy with or without aspirate is essential in all cases where treatment is considered; however, there are circumstances where it may be deferred
- Hepatitis B testing prior to initiation of treatment in all patients who will receive anti CD20 monoclonal antibody-based regimens and anyone with a risk factor
- Hepatitis C testing is needed in high-risk patients